Stage IV Squamous Cell Lung Carcinoma AJCC v7 Active Not Recruiting Phase 3 Trials for Nivolumab (DB09035)

IndicationStatusPhase
DBCOND0092102 (Stage IV Squamous Cell Lung Carcinoma AJCC v7)Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02785952Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersTreatment